Company Dossier · Health Care
CVS Health
- S&P 500
- S&P 100
- Russell 1000
What CVS Health is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $415 billion, up 7.4% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $11.8 billion, up 146% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $3.02 billion, up 8.2% from a year earlier.SEC EDGAR filings (XBRL)
- Long-term debt issued in the fiscal year to December 31, 2025: $3.97 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (August 5, 2026): sentiment 0.70 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.90 of 1.Palanor Discourse
- Guidance in the last 90 days: 3 outlook figures raised, 0 lowered, 0 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 10, 2026): 0 risk factors added, 7 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q2 2026: $324 million on the open market.SEC Form 4
- 2,079 institutional managers reported a position at June 30, 2026 (+198 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 709 (628 a year earlier).U.S. Department of Labor (OFLC)
Risk events (12 months): 2 — latest CPSC product recall, Jul 2, 2026 →
Company Posture
How Company Posture is measured →What CVS Health is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Steady · Confident
Expanding ↔ Retrenching
Steady
- Capital spending73rd pct
- Debt raised—
- Buybacks vs capex—
- Hiring filings86th pct
- Deals and private raises49th pct
- Patent publications15th pct
Confident ↔ Hedging
Confident
- Call sentiment82nd pct
- Call confidence93rd pct
- Guidance changes89th pct
- Risk factors added73rd pct
- Insider open-market trades23rd pct
- + Guidance changes
- + Call confidence
- + Call sentiment
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver71st pct
- Stress filings48th pct
Credit
How these are built →CVS Health's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$61.4B
- Due within a year $2.0B
- Longer term $59.5B
- Default point $31.7B (short + ½ long)
Finance leases included · Jun 30, 2026 filing
Bonds priced, last 12 months
None
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
| Priced | Amount | Coupon | Matures | Spread | Yield |
|---|---|---|---|---|---|
| Aug 11, 2025 | $500M | 6.250% | 2065 (40y) | +142bp | 6.277% |
| Aug 11, 2025 | $750M | 5.000% | 2032 (7y) | +102bp | 5.051% |
| Aug 11, 2025 | $1.5B | 5.450% | 2035 (10y) | +117bp | 5.453% |
| Aug 11, 2025 | $1.25B | 6.200% | 2055 (30y) | +135bp | 6.207% |
| May 7, 2024 | $750M | 6.000% | 2044 (20y) | +135bp | 6.052% |
| May 7, 2024 | $1B | 6.050% | 2054 (30y) | +150bp | 6.097% |
| May 7, 2024 | $1B | 5.400% | 2029 (5y) | +95bp | 5.421% |
| May 7, 2024 | $1B | 5.550% | 2031 (7y) | +110bp | 5.562% |
| May 7, 2024 | $1.25B | 5.700% | 2034 (10y) | +125bp | 5.709% |
From the pricing term sheets CVS Health filed with the SEC. Spread is to the benchmark Treasury (or Bund, Gilt) at pricing.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
In the news
Headlines that name CVS Health, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NeutralCVS Health (CVS) vs Cigna (CI): Which is a Better Stock to Buy?
insidermonkey.com · via Marketaux · Oct 9, 2026
- NeutralCVS Health (CVS) Declares Quarterly Dividend of $0.665 Per Share
gurufocus.com · via Marketaux · Sep 30, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 21, 2026LobbyingLobbying report (CVS HEALTH (AND SUBSIDIARIES))third_quarter 2026 · $2.0 million
- Oct 20, 2026LobbyingLobbying report (THEGROUP DC, LLC)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (MICHAEL BEST STRATEGIES LLC)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (BGR GOVERNMENT AFFAIRS)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (ALB SOLUTIONS)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (ALSTON & BIRD LLP)third_quarter 2026 · $0.0 million
- Oct 20, 2026Patent
- Oct 20, 2026Patent
- Oct 19, 2026LobbyingLobbying report (BOCKORNY GROUP, INC.)third_quarter 2026 · $0.1 million
- Oct 19, 2026LobbyingLobbying report (CONTINENTAL STRATEGY, LLC)third_quarter 2026 · $0.1 million
- Oct 6, 2026Patent
- Sep 15, 2026Patent
- Sep 8, 2026Patent
- Aug 17, 20268-KDirector or officer changeItem 5.02
- Jul 2, 2026Risk event
- May 18, 20268-KDirector or officer changeItem 5.02
- May 18, 20268-KShareholder vote resultsItem 5.07
- Mar 19, 20268-KDirector or officer changeItem 5.02
- Feb 18, 2026Risk event
- Feb 10, 202610-KAnnual report (10-K)0 risk factors added, 7 removed
- Jul 16, 2025Risk event
- Jul 1, 2025Risk event
- May 20, 20258-KShareholder vote resultsItem 5.07
- May 5, 2025Risk event
- Apr 17, 2025Risk event
- Apr 8, 20258-KDirector or officer changeItem 5.02
- Mar 12, 2025Risk event
- Feb 12, 202510-KAnnual report (10-K)0 risk factors added, 1 removed
- Feb 12, 2025Risk event
- Jan 3, 2025Risk event
- Nov 18, 20248-KMaterial agreement signedItem 1.01
- Nov 18, 20248-KDirector or officer changeItem 5.02
- Nov 6, 20248-KDirector or officer changeItem 5.02
- Nov 5, 2024Risk event
- Feb 7, 202410-KAnnual report (10-K)1 risk factors added, 1 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Cigna CI | $282B | — | Jun 30, 2026 |
| Labcorp LH | $14.3B | $1.2B | Jun 30, 2026 |
| DaVita DVA | $14.0B | $1.6B | Jun 30, 2026 |
| Quest Diagnostics DGX | $11.6B | $1.4B | Jun 30, 2026 |
| Chemed Corporation CHE | $2.6B | $0.3B | Jun 30, 2026 |
| McKesson Corporation MCK | $411B | $6.4B | Jun 30, 2026 |
| UnitedHealth Group UNH | $450B | $23.6B | Jun 30, 2026 |
| Cencora COR | $333B | $4.1B | Jun 30, 2026 |